{"id":653594,"date":"2023-05-30T11:06:01","date_gmt":"2023-05-30T11:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=653594"},"modified":"2023-05-30T11:06:01","modified_gmt":"2023-05-30T11:06:01","slug":"recurrent-or-metastatic-head-and-neck-cancer-market-expected-to-rise-eisai-co-ltd-sinocelltech-merck-nanobiotix-sichuan-baili-pharmaceutical-adlai-nortye-biopharma-biontech-pds-biotechnology","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/recurrent-or-metastatic-head-and-neck-cancer-market-expected-to-rise-eisai-co-ltd-sinocelltech-merck-nanobiotix-sichuan-baili-pharmaceutical-adlai-nortye-biopharma-biontech-pds-biotechnology_653594.html","title":{"rendered":"Recurrent or Metastatic Head and Neck cancer Market expected to rise, Eisai Co Ltd., Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1685341499.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Recurrent or Metastatic Head and Neck cancer Market expected to rise, Eisai Co Ltd., Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology\" src=\"https:\/\/www.abnewswire.com\/uploads\/1685341499.jpeg\" alt=\"Recurrent or Metastatic Head and Neck cancer Market expected to rise, Eisai Co Ltd., Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Recurrent or Metastatic Head and Neck cancer Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Recurrent or Metastatic Head and Neck cancer Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Recurrent or Metastatic Head and Neck cancer, historical and forecasted epidemiology as well as the Recurrent or Metastatic Head and Neck cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The Recurrent or Metastatic Head and Neck cancer market growth is driven by factors like increase in the prevalence of Recurrent or Metastatic Head and Neck cancer, investments in research and development, entry of emerging therapies during the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><strong>The <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/recurrent-or-metastatic-head-and-neck-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Recurrent or Metastatic Head and Neck cancer market report<\/a> also offers comprehensive insights into the Recurrent or Metastatic Head and Neck cancer market size, share, Recurrent or Metastatic Head and Neck cancer epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Recurrent or Metastatic Head and Neck cancer market size growth forward.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key highlights from the Recurrent or Metastatic Head and Neck cancer Market Insights Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Several key pharmaceutical companies, including Eisai Co Ltd., Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook.&nbsp;<\/li>\n<li>The total Recurrent or Metastatic Head and Neck cancer market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major market.<\/li>\n<li>As per DelveInsight analysis, the Recurrent or Metastatic Head and Neck cancer market is anticipated to witness growth at a considerable CAGR<\/li>\n<li>There are approx. 40+ key companies which are developing the therapies Recurrent or Metastatic Head and Neck cancer. The companies which have their Recurrent or Metastatic Head and Neck cancer drug candidates in the most advanced stage, i.e phase III include Eisai Co.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Strategise your business goals by understanding market dynamics @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/recurrent-or-metastatic-head-and-neck-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Recurrent or Metastatic Head and Neck cancer Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Recurrent or Metastatic Head and Neck cancer Overview&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">Traditionally patients with recurrence of head and neck cancer (HNC) are considered to have poor prognosis. As a result the majority of these patients are usually treated with palliative intent or receive best supportive care. Head and neck cancers are the sixth most common cancer worldwide, and arise from the upper aerodigestive mucosa, salivary glands, and skin. Despite differences in histology and biology across cancer types, most treatment protocols are extrapolated from head and neck squamous cell carcinoma (HNSCC the most common histology. Recurrent and metastatic disease is usually incurable. There are significant gaps in knowledge. Unlike other cancer types, there are no predictive biomarkers, and no new targeted therapies have been approved for HNSCC other than cetuximab in 2006.<\/p>\n<p style=\"text-align: justify;\"><strong>Do you know the treatment paradigms for different countries? Download our <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/recurrent-or-metastatic-head-and-neck-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Recurrent or Metastatic Head and Neck cancer Market Sample Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Recurrent or Metastatic Head and Neck cancer Epidemiology Segmentation&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s Recurrent or Metastatic Head and Neck cancer market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Recurrent or Metastatic Head and Neck cancer historical patient pools and forecasted Recurrent or Metastatic Head and Neck cancer patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Recurrent or Metastatic Head and Neck cancer Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Recurrent or Metastatic Head and Neck cancer Prevalence&nbsp;<\/li>\n<li>Age-Specific Recurrent or Metastatic Head and Neck cancer Prevalence&nbsp;<\/li>\n<li>Gender-Specific Recurrent or Metastatic Head and Neck cancer Prevalence&nbsp;<\/li>\n<li>Diagnosed and Treatable Cases of Recurrent or Metastatic Head and Neck cancer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Visit for more @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/recurrent-or-metastatic-head-and-neck-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Recurrent or Metastatic Head and Neck cancer Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Recurrent or Metastatic Head and Neck cancer Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The Recurrent or Metastatic Head and Neck cancer market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Recurrent or Metastatic Head and Neck cancer market trends by analyzing the impact of current Recurrent or Metastatic Head and Neck cancer therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\">This segment gives a thorough detail of Recurrent or Metastatic Head and Neck cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria&#8217;s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Recurrent or Metastatic Head and Neck cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\">According to DelveInsight, the Recurrent or Metastatic Head and Neck cancer market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Recurrent or Metastatic Head and Neck cancer Emerging Therapies and Key Companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Xevinapant: Merck<\/li>\n<li>SI B001: Sichuan Baili Pharmaceutical<\/li>\n<li>And others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Recurrent or Metastatic Head and Neck cancer Emerging Drugs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Xevinapant: Merck<\/strong><\/p>\n<p style=\"text-align: justify;\">Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care. Merck gains exclusive global development and commercialization rights; Debiopharm to receive &euro; 188 million upfront and up to &euro; 710 million in regulatory and commercial milestones, as well as royalty payments<\/p>\n<p style=\"text-align: justify;\"><strong>SI B001: Sichuan Baili Pharmaceutical<\/strong><\/p>\n<p style=\"text-align: justify;\">SI B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR&times;EGFR homodimers, the formation of EGFR&times;HER3 heterodimers and the activation of its downstreamsignal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, anddown-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy.<\/p>\n<p style=\"text-align: justify;\"><strong>For more information, visit <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/recurrent-or-metastatic-head-and-neck-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Recurrent or Metastatic Head and Neck cancer Market Analysis, Patient Pool, and Emerging Therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Recurrent or Metastatic Head and Neck cancer Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>11 Years Forecast<\/li>\n<li>7MM Coverage&nbsp;<\/li>\n<li>Descriptive overview of Recurrent or Metastatic Head and Neck cancer, causes, signs and symptoms, diagnosis, treatment<\/li>\n<li>Comprehensive insight into Recurrent or Metastatic Head and Neck cancer epidemiology in the 7MM<\/li>\n<li>Recurrent or Metastatic Head and Neck cancer marketed and emerging therapies&nbsp;<\/li>\n<li>Recurrent or Metastatic Head and Neck cancer companies<\/li>\n<li>Recurrent or Metastatic Head and Neck cancer market drivers and barriers&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key Questions Answered in the Recurrent or Metastatic Head and Neck cancer Market Report 2032:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What was the Recurrent or Metastatic Head and Neck cancer market share distribution in 2019, and how would it appear in 2032?<\/li>\n<li>What is the total Recurrent or Metastatic Head and Neck cancer market size and the market size by therapy across the 7MM for the study period (2019-32)?<\/li>\n<li>What are the important findings from 7MM, and which country will have the greatest Recurrent or Metastatic Head and Neck cancer market size from 2019-32?<\/li>\n<li>During the study period (2019-2032), at what CAGR is the Recurrent or Metastatic Head and Neck cancer market projected to expand at 7MM?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1 Recurrent or Metastatic Head and Neck cancer Market Key Comprehensive Insights&nbsp;<\/p>\n<p style=\"text-align: justify;\">2 Recurrent or Metastatic Head and Neck cancer Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">3 Competitive Intelligence Analysis for Recurrent or Metastatic Head and Neck cancer<\/p>\n<p style=\"text-align: justify;\">4 Recurrent or Metastatic Head and Neck cancer Market Analysis Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5 Executive Summary of Recurrent or Metastatic Head and Neck cancer<\/p>\n<p style=\"text-align: justify;\">6 Recurrent or Metastatic Head and Neck cancer Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">7 Recurrent or Metastatic Head and Neck cancer Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8 Recurrent or Metastatic Head and Neck cancer Patient Journey<\/p>\n<p style=\"text-align: justify;\">9 Recurrent or Metastatic Head and Neck cancer Treatment Algorithm, Recurrent or Metastatic Head and Neck cancer Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10 Key Endpoints in Recurrent or Metastatic Head and Neck cancer Clinical Trials<\/p>\n<p style=\"text-align: justify;\">11 Recurrent or Metastatic Head and Neck cancer Marketed Therapies&nbsp;<\/p>\n<p style=\"text-align: justify;\">12 Recurrent or Metastatic Head and Neck cancer Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13 Recurrent or Metastatic Head and Neck cancer: 7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14 Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15 Access and Reimbursement Overview of Recurrent or Metastatic Head and Neck cancer<\/p>\n<p style=\"text-align: justify;\">16 Recurrent or Metastatic Head and Neck cancer Market Key Opinion Leaders Reviews<\/p>\n<p style=\"text-align: justify;\">18 Recurrent or Metastatic Head and Neck cancer Market Drivers<\/p>\n<p style=\"text-align: justify;\">19 Recurrent or Metastatic Head and Neck cancer Market Barriers<\/p>\n<p style=\"text-align: justify;\">20 SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">21 Disclaimer<\/p>\n<p style=\"text-align: justify;\">22 DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">23 About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Recurrent or Metastatic Head and Neck cancer Epidemiology 2032<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;Recurrent or Metastatic Head and Neck cancer &#8211; Epidemiology Forecast to 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted Recurrent or Metastatic Head and Neck cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Recurrent or Metastatic Head and Neck cancer Pipeline 2023<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Recurrent or Metastatic Head and Neck cancer Pipeline Insights, 2023&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Recurrent or Metastatic Head and Neck cancer market. A detailed picture of the Recurrent or Metastatic Head and Neck cancer pipeline landscape is provided, which includes the disease overview and Recurrent or Metastatic Head and Neck cancer treatment guidelines.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=recurrent-or-metastatic-head-and-neck-cancer-market-expected-to-rise-eisai-co-ltd-sinocelltech-merck-nanobiotix-sichuan-baili-pharmaceutical-adlai-nortye-biopharma-biontech-pds-biotechnology\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=recurrent-or-metastatic-head-and-neck-cancer-market-expected-to-rise-eisai-co-ltd-sinocelltech-merck-nanobiotix-sichuan-baili-pharmaceutical-adlai-nortye-biopharma-biontech-pds-biotechnology\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recurrent or Metastatic Head and Neck cancer Market DelveInsight&#8217;s &#8220;Recurrent or Metastatic Head and Neck cancer Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Recurrent or Metastatic Head and Neck cancer, historical and forecasted epidemiology &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/recurrent-or-metastatic-head-and-neck-cancer-market-expected-to-rise-eisai-co-ltd-sinocelltech-merck-nanobiotix-sichuan-baili-pharmaceutical-adlai-nortye-biopharma-biontech-pds-biotechnology_653594.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-653594","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=653594"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/653594\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=653594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=653594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=653594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}